Aristea Therapeutics, Inc. — Form D/A
Aristea Therapeutics, Inc. of SAN DIEGO, CA, a company, filed a Form D amendment with the SEC on 2021-08-05. The offering totals $63.1M, of which $63.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-08-05
- Form: D/A
- Accession: 0001829049-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $63.1M
- Amount sold: $63.1M
- Remaining: $6
- Investors: 15
- Date of first sale: 2020-10-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-378342
Issuer
- Name: Aristea Therapeutics, Inc.
- CIK: 0001829049
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 12770 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
- Phone: 858-987-4064
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Tiba Aynechi | Director | South San Francisco, CA |
| Kenneth Harrison | Director | Half Moon Bay, CA |
| Ciara Kennedy | Director | San Diego, CA |
| James Mackay | Director | San Diego, CA |
| Loretta Tse | Director | San Diego, CA |
| James Mackay | Executive Officer | San Diego, CA |
Other filings by this issuer (1)
More